| 25.4.2022 | EN | Official Journal of the European Union | C 171/28 |
Judgment of the General Court of 2 March 2022 — Degode- v EUIPO — Leo Pharma (Skinovea)
(Case T-715/20) (1)
(EU trade mark - Opposition proceedings - Application for the EU word mark Skinovea - Earlier national word mark SKINOREN - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)
(2022/C 171/36)
Language of the case: English
Parties
Applicant: Degode-Dermago Development GmbH (Strausberg, Germany) (represented by: O. Spieker, A. Schönfleisch and N. Willich, lawyers)
Defendant: European Union Intellectual Property Office (represented by: M. Capostagno and V. Ruzek, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO: Leo Pharma A/S (Ballerup, Denmark)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 4 September 2020 (Case R 337/2020 5) relating to opposition proceedings between Leo Pharma and Degode-Dermago Development.
Operative part of the judgment
The Court:
| 1. | Dismisses the action; |
| 2. | Orders Degode-Dermago Development GmbH to pay the costs. |
(1) OJ C 35, 1.2.2021.